Uterine myoma. Leiomyoma of uterus, unspecified
Conditions
Interventions
Intervention 1: The intervention group: Letrozole ( Made in Iran , Iran hormone ) 2.5 mg per day and Dostinex (Made in Iran , the company Aboureihan ) 0.5 mg per week for 12 weeks from the first day
Treatment - Drugs
The intervention group: Letrozole ( Made in Iran , Iran hormone ) 2.5 mg per day and Dostinex (Made in Iran , the company Aboureihan ) 0.5 mg per week for 12 weeks from the first day of the period
In the control group:Letrozole ( Made in Iran , Iran hormone ) 2.5 mg per day of the first day of the period
Sponsors
Vice chancellor for Research,Tabriz University Of Medical Sciences
Eligibility
Sex/Gender
Female
Age
No minimum to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women with Myoma larger than 4 cm and irregular menstrual cycle; Candidate for myomectomy or hysterectomy or treatment of infertility Exclusion criteria: Age over 45 years; Uterine disease; Kidney disease; Liver disease; Antipsychotic drugs; Patients with history of use estrogen and progesterone in the last month; Patients with a history of drug treatment or surgery for uterine myoma and uterine bleeding
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deterioration of uterine myoma. Timepoint: 12 weeks after starting treatment. Method of measurement: Ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Menstrual regulation. Timepoint: After treatment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Manizheh Sayyah-Melli
Tabriz University Of Medical Sciences
Outcome results
None listed